Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials

Authors

Andy Lin

Published

September 11, 2019

Abstract

CRISPR reveals that many cancer drug targets are dispensable for cell proliferation and identifies CDK11 as the target of one mischaracterized agent.

Supporters

Support the authors with ResearchCoin

Journal

Science Translational Medicine

Topics

DOI

10.1126/scitranslmed.aaw8412

Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials

Authors

Andy Lin

Published

September 11, 2019

Abstract

CRISPR reveals that many cancer drug targets are dispensable for cell proliferation and identifies CDK11 as the target of one mischaracterized agent.

Supporters

Support the authors with ResearchCoin

Journal

Science Translational Medicine

Topics

DOI

10.1126/scitranslmed.aaw8412

Paper

Paper

Paper

Paper

Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials

Abstract

Supporters

Journal

Topics

DOI

Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials

Abstract

Supporters

Journal

Topics

DOI